Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)
This study has been completed.
Information provided by (Responsible Party):
First received: May 2, 2002
Last updated: November 19, 2013
Last verified: November 2013
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.
Major Depressive Disorder
Drug: MK0869, aprepitant
Drug: Comparator: placebo
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Merck:
Primary Outcome Measures:
- HAMD-17 total score at week 8. Tolerability.
Secondary Outcome Measures:
- CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.
|Study Start Date:||January 2002|
|Study Completion Date:||December 2003|
|Primary Completion Date:||December 2003 (Final data collection date for primary outcome measure)|
The duration of treatment is 8 weeks.
Contacts and Locations
No Contacts or Locations Provided